



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** November 6, 2009

**To:** Primary Clinical Research Associates

**From:** Linda S. Long  
Protocol Development Coordinator

**Re:** N054C, Phase II Study of Sorafenib/Bevacizumab as Salvage Therapy in Patients with Metastatic Colorectal Cancer

The Eligibility Checklist and Blood Specimen Submission Form have been revised as follows:

<b>Form Title</b>	<b>Brief Description of Edit</b>
Eligibility Checklist	<b>First Exclusion Criteria, page 3 of 5 read:</b> <ul style="list-style-type: none"><li>• Was treatment held this cycle? . . . for at least 2 weeks after the last administration of sorafenib.</li></ul> <b>Now reads:</b> <ul style="list-style-type: none"><li>• Was treatment held this cycle? . . . for at least <b>6 months after the last administration of combined sorafenib and bevacizumab or for at least 2 weeks</b> after the last administration of sorafenib.</li></ul>
Blood Specimen Submission Form	<b>First bullet under Instructions read:</b> <ul style="list-style-type: none"><li>• Complete . . . within 7 days of study entry (Baseline) or within 7 days of specimen collection.</li></ul> <b>Corrected to read (per section 14.251):</b> <ul style="list-style-type: none"><li>• Complete . . . <b>≤ 14 days of specimen collection.</b></li></ul>

If you have any questions, please feel free to contact me.

Enclosure